摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-肼基-4-甲基吡啶 | 4931-00-4

中文名称
2-肼基-4-甲基吡啶
中文别名
——
英文名称
2-hydrazinyl-4-methylpyridine
英文别名
2-Hydrazino-4-methyl-pyridin;2-hydrazino-4-methylpyridine;4-methyl-2-pyridylhydrazine;(4-methylpyridin-2-yl)hydrazine
2-肼基-4-甲基吡啶化学式
CAS
4931-00-4
化学式
C6H9N3
mdl
MFCD09863246
分子量
123.158
InChiKey
FNFPJUDYICAQSZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    74 °C
  • 沸点:
    88-89 °C(Press: 0.02 Torr)
  • 密度:
    1.16±0.1 g/cm3(Predicted)
  • 溶解度:
    可溶于DMSO(少许)、甲醇(少许)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    50.9
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    -20°C,避光,惰性气体

SDS

SDS:59d00bd43ed22664343cee6b3351d724
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Hydrazino-4-methylpyridine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Hydrazino-4-methylpyridine
CAS number: 4931-00-4

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H9N3
Molecular weight: 123.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    2-肼基-4-甲基吡啶2-吡啶甲酸potassium phosphatecopper(l) iodidepotassium carbonate 作用下, 以 乙醇二氯甲烷二甲基亚砜 为溶剂, 反应 69.0h, 生成 3-(3-(tert-butyl)-5-(3-((4-methylpyridin-2-yl)oxy)phenoxy)phenyl)-7-methyl-[1,2,4]triazolo[4,3-a]pyridine
    参考文献:
    名称:
    基于[1,2,4]含三唑并[4,3-a]吡啶的配体的金属辅助延迟荧光Pd(II)配合物和磷光Pt(II)配合物:合成,表征,电化学,光物理研究和应用
    摘要:
    报道了一系列四齿环金属化的M(tzp Ph-O-CzPy-R)配合物及其类似物的合成和光物理性质,其中M为钯或铂,四齿环金属化配体包含tzp Ph(3-苯基-[1 ,2,4]三唑并[4,3- a ]吡啶)和CzPy(咔唑基吡啶)部分与氧原子相连。配体上的σ电子给体基团R的变化会显着影响复合物的光物理性质。通过使用强大的吸电子tzp部分作为受体,咔唑部分作为供体,开发了一系列基于Pd(II)的金属辅助延迟荧光(MADF)材料。电化学分析表明不可逆的还原过程发生在tzp环上,不可逆的氧化过程主要发生在金属-苯基部分上。这与通过DFT计算得到的HOMO和LUMO分布一致,这也表明Pt(II)配合物比Pd(II)配合物具有更多的金属轨道特性。此处报道的大多数Pd(II)配合物在2-MeTHF中在77 K时都具有高发射率,发光寿命在毫秒范围内(τ= 1.96–2.36 ms),并且λmax= 488–499
    DOI:
    10.1021/acs.inorgchem.9b01617
  • 作为产物:
    描述:
    2-溴-4-甲基吡啶一水合肼 作用下, 以 乙醇 为溶剂, 反应 24.0h, 生成 2-肼基-4-甲基吡啶
    参考文献:
    名称:
    1,2,3,4-四唑的双重反应:锰催化的点击反应和脱氮环化反应。
    摘要:
    据报道,使用基于锰卟啉的催化系统的一般催化方法可实现两种不同的反应(点击反应和脱氮环化反应),并提供两种不同类型的氮杂环,即1,5-二取代的1,2,3-三唑(具有吡啶基)和1,2,4-三唑并吡啶。机理研究表明,尽管点击反应可能是通过离子机理进行的,这与传统的点击反应不同,但脱氮环化反应可能是通过亲电子的茂金属中间体而不是金属金属中间体进行的。总体而言,此方法非常高效,与其他方法相比,具有许多优点。例如,2副产品产生气体。
    DOI:
    10.1002/anie.202009078
  • 作为试剂:
    描述:
    5-Pyren-4-ylpentan-2-one 在 2-肼基-4-甲基吡啶对甲苯磺酸 、 bis(1,5-cyclooctadiene)iridium(I) tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 、 1,1-双(二苯基膦)乙烯1,3-丁二烯 作用下, 以 1,4-二氧六环甲苯 为溶剂, 反应 77.0h, 以36%的产率得到4,5-dihydro-3H-benzo[cd]pyrene
    参考文献:
    名称:
    通过未应变酮的 C-C 裂解脱酰化辅助 C-H 烷基化环化
    摘要:
    芳烃和杂芳烃稠合环普遍存在于生物活性分子中。芳香核心上的 C-H 键和连接的烷基部分之间的直接环化提供了一种直接接近这些支架的方法;然而,这种策略通常会因需要特殊的反应基团和/或不太相容的环化条件而受到阻碍。如果可以使用一个共同的天然官能团作为手柄来实现具有不同芳香环的通用 C-H 环化,那将具有综合吸引力。在这里,我们展示了一种脱酰基环化策略,用于从线性简单酮前体制备多种芳族稠环。该反应首先通过前芳族中间体均裂酮α C-C 键,然后是自由基介导的脱氢环化。
    DOI:
    10.1038/s41929-021-00661-7
点击查看最新优质反应信息

文献信息

  • The Base-Promoted Annulation of 2-Hydrazinyl Pyridine and CO<sub>2</sub> toward Triazolones
    作者:Xiaopeng Wu、Song Sun、Bingbing Wang、Jiang Cheng
    DOI:10.1002/adsc.201700869
    日期:2017.11.10
    A base‐promoted annulation of 2‐hydrazinyl pyridine and atmospheric pressure of CO2 has been developed in the presence of silane as reducing reagent, affording a series of triazolones in moderate to excellent yields. CO2 served as a carbonyl source in this transfomation. Moreover, benzamidrazones also worked well under this procedure. Thus, it represents a green, sustainable and straightforward pathway
    在硅烷作为还原剂存在下,开发了碱促进的2-肼基吡啶环化反应和大气压下的CO 2,可提供中等至极好的收率的三唑酮系列。在这种转化过程中,CO 2用作羰基来源。此外,苯并dra唑酮在该程序下也能很好地工作。因此,它代表了访问三唑酮框架的绿色,可持续和直接途径。
  • SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES
    申请人:Thede Kai
    公开号:US20100305085A1
    公开(公告)日:2010-12-02
    The invention relates to dihydropyrazolon-derivatives of formula (I), to methods for their production, to their use for treating and/or for preventing diseases and their use for producing medicaments for treating and/or for preventing diseases, in particular cardiovascular and haematological diseases, kidney diseases and for promoting the healing of wounds.
    这项发明涉及式(I)的二氢吡唑酮衍生物,以及它们的生产方法,它们用于治疗和/或预防疾病以及用于生产治疗和/或预防疾病的药物,特别是心血管和血液疾病、肾脏疾病以及促进伤口愈合的用途。
  • Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia
    作者:Hartmut Beck、Mario Jeske、Kai Thede、Friederike Stoll、Ingo Flamme、Metin Akbaba、Jens-Kerim Ergüden、Gunter Karig、Jörg Keldenich、Felix Oehme、Hans-Christian Militzer、Ingo V. Hartung、Uwe Thuss
    DOI:10.1002/cmdc.201700783
    日期:2018.5.23
    4‐diheteroaryl‐1,2‐dihydro‐3H‐pyrazol‐3‐ones as orally bioavailable HIF‐PH inhibitors for the treatment of anemia. High‐throughput screening of our corporate compound library identified BAY‐908 as a promising hit. The lead optimization program then resulted in the identification of molidustat (BAY 85‐3934), a novel small‐molecule oral HIF‐PH inhibitor. Molidustat is currently being investigated in clinical phase III
    缺氧诱导因子脯氨酰羟化酶(HIF-PH)的小分子抑制剂目前正在临床开发中,作为慢性肾病(CKD)相关贫血的新治疗选择。HIF-PH 的抑制模拟缺氧并导致促红细胞生成素 (EPO) 表达增加,从而增加红细胞生成。在此,我们描述了新型 2,4-二杂芳基-1,2-二氢-3 H-吡唑-3-酮类药物的发现、合成、结构-活性关系 (SAR) 和拟议的结合模式,作为口服生物可利用的 HIF- PH抑制剂贫血的治疗。对我们公司化合物库的高通量筛选确定 BAY-908 是一个有前景的热门产品。先导化合物优化计划最终鉴定出莫度司他 (BAY 85-3934),这是一种新型小分子口服 HIF-PH 抑制剂。Molidustat 目前正在临床 III 期试验中研究作为 molidustat 钠用于治疗 CKD 患者贫血。
  • Catalytic Coupling between Unactivated Aliphatic C–H Bonds and Alkynes via a Metal–Hydride Pathway
    作者:Yan Xu、Michael C. Young、Guangbin Dong
    DOI:10.1021/jacs.7b02020
    日期:2017.4.26
    We report a Rh(I)-catalyzed site-selective coupling between ketone β-C(sp3)-H bonds and aliphatic alkynes using an in situ-installed directing group. Upon hydrogenation or hydration, various β-alkylation or β-aldol products of the ketones are obtained with broad functional group tolerance. Mechanistic investigations support the involvement of a Rh-H intermediate through oxidative addition of Rh(I)
    我们报告了使用原位安装的导向基团在酮 β-C(sp3)-H 键和脂肪族炔烃之间进行 Rh(I) 催化的位点选择性偶联。通过氢化或水合,得到具有广泛官能团耐受性的酮的各种β-烷基化或β-羟醛产物。机理研究支持通过将 Rh(I) 氧化加成到 β-CH 键中来参与 Rh-H 中间体。因此,据我们所知,这种转变代表了不饱和烃和未活化的脂肪族 CH 键通过金属氢化物途径进行催化偶联的第一个例子。
  • [EN] TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS<br/>[FR] COMPOSÉS TRIAZOLOPYRIDINE COMME INHIBITEURS DE LA PIM KINASE
    申请人:ARRAY BIOPHARMA INC
    公开号:WO2010022076A1
    公开(公告)日:2010-02-25
    Compounds of Formula (I), in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.
    公式(I)的化合物,其中A、B、R1、R1a、R2、R3、R4、R5、R6和R7的含义如规范中所述,是在治疗免疫细胞相关疾病和紊乱方面有用的受体酪氨酸激酶抑制剂,例如炎症性和自身免疫疾病。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-